News

“This new procedure we specifically engineered for Fred has never been done before but it replicates a bypass operation performed in the 1950s,” said Dr. O’Neill.

ENTRUST is a randomized, double-blind, placebo-controlled global trial that is planned to enroll up to 360 severe hypertriglyceridemia patients.

“When the war started, myself and others on my team decided to stay at work to do our best to help our people, soldiers, neighbors and relatives to survive. But we decided it was not enough to only maintain, but that we must develop and raise...

The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication,...

The $115,000 fellowship opportunity was made possible by support from Abiomed (founding supporter), Boston Scientific, Medtronic, and Shockwave Medical, Inc., and is offered to interventional cardiology (IC) fellows or practicing...

PHOENIX (May 20, 2023) – Today during the SCAI 2023 Scientific Sessions, thirty early-career interventional cardiologists were the inaugural recipients of a newly created award highlighting excellence in interventional cardiology....

Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemaker

SIRONA 2 is an open-label, single-arm trial of 70 European patients that met its primary endpoints for safety and accuracy with the previously reported 90-day results. The 12-month results extended both the strong safety profile.